There is no TGA-registered BPC-157 product for therapeutic use in Australia, and as of June 2024 BPC-157 is a Schedule 4 (prescription-only) substance, meaning any legal supply must come through a doctors prescription via a compounding pharmacy
For example, Edaravone is a small molecule antioxidative drug used to repair brain oxidative injury, but its short halflife and low bioavailability greatly limit its efficacy and clinical application [62, 63, 64, 65, 66]
Rajagopal Sekhar at Baylor College of Medicine for supporting glutathione levels, oxidative stress markers, and mitochondrial function in aging adults
Mrazek, D
But in practice, and especially with regard to synthetic and recombinant peptide forms, there are some considerable potential safety concerns: Immunogenicity Most notably, per a 2020 assessment on therapeutic peptide safety, synthetic and recombinant peptides pose the risk of immunogenicity the ability of a substance to provoke an immune response.15 An immunogenicity-inducing peptide, when introduced to the body, would cause the bodys immune system to perceive the peptide not as a medication but as a threat
Oral water was associated with an increase in VO 2 up to the final time point of the study, and this effect was not observed in the control group
